Tempus AI, backed by Google, experiences a 15% increase in stock value during its Nasdaq debut.

• On Friday, Tempus AI experienced a 15% increase in its market value on the Nasdaq, where it debuted under the ticker symbol "TEM."
• In 2020 and 2021, Tempus AI was recognized as a disruptor by CNBC and made it onto their Disruptor 50 lists.
• On Thursday, the Chicago-based health-care diagnostics company sold 11 million shares at $37 each, which was at the upper end of its initial price range of $35 to $37.

On Friday, Tempus AI, a health-care diagnostics company that employs AI to analyze medical tests and aid physicians in providing precise treatment to their patients, experienced a 15% increase in its Nasdaq Stock Market debut. The company is now trading under the ticker symbol "TEM."

On Thursday, Tempus AI sold 11.1 million shares at $37 each, within its initial price range of $35 to $37. The company raised $410 million at an implied valuation of $6 billion. If its early gains hold, Tempus AI will be valued at approximately $7 billion.

In 2023, Tempus generated a total revenue of $531.8 million and a net loss of $214.1 million, with the belief that AI can assist in therapy selection and treatment decisions in collaboration with the patient's doctor.

Eric Lefkofsky, CEO of Tempus AI, stated on CNBC's "Squawk Box" that the company is on a positive trajectory. He explained that revenues have been growing quickly, and the company is not investing all of its gross profit dollar growth back into the business. Instead, Tempus AI is generating improved leverage every quarter. Lefkofsky added that he expects the company to be both cash flow and EBITDA positive within the next year.

The application of heavily-funded technology concepts such as artificial intelligence and data analysis by Tempus AI is aimed at improving the medical profession and providing better, more informed healthcare. Despite the maturity of our healthcare infrastructure, the lack of diagnostic testing early in the Covid-19 outbreak demonstrated how even well-prepared systems can still be caught off guard by future challenges.

The Chicago-based company stated in its IPO filing that its goal is to harness the full potential of precision medicine through the use of Intelligent Diagnostics, which employ artificial intelligence (AI) to improve the accuracy, customization, and personalization of laboratory tests. Intelligent Diagnostics leverage AI technologies, including generative AI, to analyze and interpret laboratory results in conjunction with a patient's clinical data, resulting in personalized, tailored diagnoses.

The at-home testing kit of the two-time CNBC Disruptor 50 company was rapidly rolled out during the pandemic, but the problem Tempus is attacking is not Covid-specific. The Tempus idea came to Lefkofsky, also known for co-founding Groupon, during frustration with the health-care system after his wife received a breast cancer diagnosis. Oncology is a primary focus and the company's genomic tests are designed to understand tumors at the molecular level and tailor treatment to individuals.

Tempus AI's offering was underwritten by J.P. Morgan, Morgan Stanley, and Allen & Company as lead underwriters.

According to PitchBook data, the investors include Google, Baillie Gifford, Franklin Templeton, NEA, and T. Rowe Price.

— CNBC's Bob Pisani contributed to this reporting.